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1. INTRODUCTION {#emp212230-sec-0050}
===============

1.1. Background {#emp212230-sec-0060}
---------------

The World Health Organization has called the current severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic the "defining health crisis of our time."[^1^](#emp212230-bib-0001){ref-type="ref"} After its discovery in December 2019, the virus spread to metropolitan areas across the globe, leading to early and sustained community spread in certain areas including metropolitan Los Angeles. Despite large numbers of people being infected, little work has been done to characterize outcomes among relatively low‐risk patients with suspected or confirmed illness who present to the emergency department or outpatient settings.

1.2. Importance {#emp212230-sec-0070}
---------------

Published guidance suggests that disposition home is appropriate for patients with mild symptoms and few comborbidities.[^2^](#emp212230-bib-0002){ref-type="ref"}, [^3^](#emp212230-bib-0003){ref-type="ref"} However, there is minimal evidence describing post‐discharge outcomes for patients who are well appearing at the time of ED evaluation. Prognostic evidence from China suggests that 80% of patients have mild illness, 15% require oxygen, and 5% require ICU monitoring.[^4^](#emp212230-bib-0004){ref-type="ref"} Currently in the United States, however, it is unknown how often patients evaluated in the ED seek subsequent care for worsening symptoms after their initial evaluation and how often they undergo monitoring in the inpatient and ICU settings.

1.3. Goals of this investigation {#emp212230-sec-0080}
--------------------------------

The primary goal of this investigation was to describe outcomes for low‐risk patients discharged home from the ED, including rates of ED revisit, inpatient admission, and ICU admission within 30 days.

2. METHODS {#emp212230-sec-0090}
==========

2.1. Study design and setting {#emp212230-sec-0100}
-----------------------------

This study is reported in accordance with the STROBE (Strengthening the Reporting of Observational studies in Epidemiology) statement.[^5^](#emp212230-bib-0005){ref-type="ref"} This was a retrospective cohort study of consecutive patients with suspected coronavirus disease 2019 (COVID‐19) in whom clinical and phone follow‐up data had been compiled as a quality improvement initiative during the early COVID‐19 pandemic. The study was conducted at an urban ED at an academic medical center in the Los Angeles metropolitan area with ≈90,000 visits per year.

2.2. Selection of participants {#emp212230-sec-0110}
------------------------------

Patients were selected for inclusion in the study if they were evaluated for influenza‐like illness suggestive of COVID‐19 in a temporary surge tent between March 12, 2020 and April 6, 2020 and discharged home. Patients were excluded from the study if they had been seen in our ED within the prior 7 days, if they did not complete ED evaluation (ie, left without being seen, left against medical advice, or eloped), or if they were asymptomatic according to clinician documentation.

### The Bottom Line {#emp212230-sec-0120}

The majority of patients diagnosed with coronavirus disease 2019 from US emergency departments are discharged and subsequent ED revisit, admission, ICU admission, and death rates are unknown. This retrospective study of 30‐day follow up in 452 ED patients reported that a minority of low‐risk patients require subsequent hospital admission.

2.3. Treatment and disposition pathway {#emp212230-sec-0130}
--------------------------------------

Patients were assessed by emergency physicians or physician assistants who were given guidelines to (1) minimize testing (ie, avoid unnecessary blood tests and advanced imaging) and (2) optimize time spent in educating patients about COVID‐19, its typical progression, isolation instructions, and return precautions. Testing in the tent itself was limited to SARS‐CoV‐2 polymerase chain reaction (PCR) nasopharyngeal swabs, chest radiographs, and electrocardiograms; however, some patients initially triaged to the tent were ultimately sent to the main ED for a more comprehensive workup including blood testing at the discretion of the clinician. COVID‐19 PCR tests were performed initially through the Los Angeles County Department of Public Health and Quest Diagnostics. Later during the study period and after approval by the Federal Drug Administration, Cedars‐Sinai Medical Center\'s laboratory performed COVID‐19 PCR tests on site rather than sending them to the County or Quest. The clinician\'s decision to test for COVID‐19 was informed by evolving guidelines from the Centers for Disease Control and Prevention and the Los Angeles County Department of Public Health. Results of COVID‐19 testing performed in the ED were not available at the time of the ED visit. Outpatient management of suspected COVID‐19 cases was encouraged if patients met criteria listed in Box 1, regardless of whether COVID‐19 testing was performed. These criteria were developed by our department leadership after review of available guidance in March 2020, including 1 relevant peer‐reviewed publication and a report from the World Health Organization.[^6^](#emp212230-bib-0006){ref-type="ref"}, [^7^](#emp212230-bib-0007){ref-type="ref"} Suggested discharge criteria were communicated to ED clinicians during a 10‐minute presentation during departmental grand rounds and also through distribution by email. In the same presentation, hospitalization was discouraged given the absence of proven prophylactic or therapeutic treatment options and to preserve inpatient resources for an anticipated wave of higher acuity patients.

### 1. Box 1: Discharge criteria for patients with suspected COVID‐19 infection {#emp212230-sec-0140}

Resting pulse oximeter ≥ 92%

No respiratory distress or tachypnea (respiratory rate ≤ 20) at rest

≤ 60 years of age

Ambulatory

No significant comorbidities

No more than mild disease on chest radiograph (if obtained)

Ability to return within 24 hours if worse

Patient preference for outpatient management

2.4. Data collection {#emp212230-sec-0150}
--------------------

ED administrative staff obtained data used in this study during a quality improvement initiative designed to ascertain outcomes of patients cared for in the ED\'s surge tent during the early COVID‐19 pandemic. Data collection involved review of the electronic health record (EHR) as well as phone follow‐up to patients to characterize follow‐up care received and the total duration of symptoms. Data collection was performed via a combination of automatic data exportation through Epic reports (most structured data elements) and human entry into a spreadsheet (vital signs, number of days of symptoms prior to ED visit) by 2 operations team members with experience in healthcare delivery (AJH: emergency medical technician; NCG, physician assistant). These case reviews were performed as independent, unblinded reviews. One physician member of the team (CTB) supervised data collection. Two physicians (CTB and SST) reviewed cases that included outcomes of interest to ensure accurate reporting.

Data elements collected from the EHR include patient characteristics (age, sex, race, ethnicity, comorbidities); visit characteristics (day of week, arrival time, length of stay, emergency severity index triage score); clinical characteristics (chief complaint, vital signs, duration of symptoms prior to ED visit), and testing performed in the ED (chest radiography, electrocardiogram, influenza test, COVID‐19 PCR test, and any blood work). The number of comorbidities was generated by counting certain conditions (hypertension, cardiovascular disease, lung disease, chronic kidney disease, obesity, and immunosuppression) documented in the patient\'s past medical history. The chief complaint was extracted as documented by the triage nurse. Because it was common for triage chief complaints to include free‐text or multiple complaints, 1 physician member of the research team (CTB) consolidated the chief complaints using the following stepwise process: (1) counted first‐listed chief complaints and listed them in order of most frequent to least frequent; (2) consolidated similar complaints (eg, combined "fever" with "chills"; combined "influenza‐like illness" with "flu"); and (3) combined remaining chief complaints occurring \<8 times into clinically relevant categories (eg, combined rhinorrhea and ear pain).

Through phone follow‐up at 30 days after the visit, patients (or caregivers) were asked to provide information about any care received after the ED visit, including dates of subsequent ED visits, inpatient admissions, ICU admissions, and/or deaths. The patient was also asked to recall the total duration of their symptoms and/or the date that symptoms resolved. If symptoms were reported as still ongoing, symptom duration was capped at \>30 days. If the patient or caregiver was not reachable after 2 attempts by phone, the team sought information about vital status and timing of any subsequent care through our medical center\'s EHR and its CareEverywhere feature. Any patient care activity \>30 days after the index visit was considered to be confirmation the patient survived the 30‐day follow‐up period. County coroner data were queried using an online tool. Complete death certificate data were not available at the time of publication because of proximity of the visit date and preparation of the manuscript.

All data were stored in a password‐protected database that was maintained on an encrypted server.

2.5. Outcomes {#emp212230-sec-0160}
-------------

The primary outcomes of interest were ED revisits, inpatient admissions, ICU admissions, and deaths within 30 days of the index visit. Secondary outcomes were measured through patients' self‐reported duration of symptoms including symptom onset and symptom resolution.

2.6. Analysis {#emp212230-sec-0170}
-------------

We performed a descriptive analysis of patient and visit characteristics using STATA version 13.1 (StataCorp, College Station, TX). Additionally, 2 research team members (CTB and AJH) reviewed cases that resulted in ED revisits to determine reasons that patients cited for returning to the ED and described their findings in the supplementary appendix. The institutional review board approved this study as non‐human subjects research because we utilized an already‐existing ED operations database.

3. RESULTS {#emp212230-sec-0180}
==========

Of 504 patients screened, 452 patients met inclusion criteria (Figure [1](#emp212230-fig-0001){ref-type="fig"}). The median age was 38 (interquartile range \[IQR\] 30--51.5); 98.7% of patients were adults, 50.9% were women, and 61.7% had no significant comorbidities. The median duration of symptoms at the time of index ED evaluation was 4 days (IQR 2--7, range 0--60). The most commonly abnormal vital sign was the heart rate \>100 in 103/452 (22.8%) patients, followed by respiratory rate \>20 in 36/452 (8.0%) patients. Temperature of \>100.4°F was present in the ED in 19/452 (4.2%), and all patients had oxygen saturation of 92% or higher. Chest radiographs were the most commonly ordered test, performed in 228/452 (50.4%) patients with infiltrates present on 32/452 (7.1%) of patients, which was 32/228 (14.0%) of those imaged. Nasopharyngeal PCR testing for SARS‐CoV‐2 was performed in 128/452 (28.3%) of patients the during the ED visit and returned positive results in 46/452 (10.2%), which was 46/128 (35.9%) of those tested. A total of 62/452 (13.7%) patients in our sample had positive COVID‐19 testing during the 30 days following the index visit. See Table [1](#emp212230-tbl-0001){ref-type="table"} for additional patient characteristics and clinical outcomes for the study population.

![Flowsheet demonstrating numbers of patients excluded, follow‐up success, and outcomes for patients in the study cohort. AMA, against medical advice; LWBS, left without being seen.](EMP2-9999-na-g002){#emp212230-fig-0001}

###### 

Patient characteristics and clinical outcomes

  Characteristics                                                                                      N = 452 (%)
  ------------------------------------------ --------------------------------------------------------- ------------------------------
  Age                                        0--17                                                     6 (1.3)
                                             18--34                                                    180 (39.8)
                                             35--49                                                    136 (30.1)
                                             50--64                                                    89 (19.7)
                                             65--79                                                    41 (9.1)
  Sex                                        Female                                                    230 (50.9)
                                             Male                                                      222 (48.1)
  Race                                       White                                                     313 (69.2)
                                             Black                                                     67 (14.8)
                                             Asian                                                     26 (5.8)
                                             *Missing*                                                 46 (10.2)
  Ethnicity                                  Non‐Hispanic                                              360 (79.6)
                                             Hispanic                                                  86 (19.0)
                                             *Missing*                                                 6 (0.3)
  Number of comorbidities                    0                                                         279 (61.7)
                                             1                                                         111 (24.6)
                                             2                                                         34 (7.5)
                                             3 or more                                                 28 (6.2)
  Time of arrival                            7 am‐3 pm                                                 232 (51.3)
                                             3 pm‐11 pm                                                220 (48.7)
  Day of week                                Weekday                                                   362 (80.1)
                                             Weekend                                                   90 (19.9)
  Length of stay (minutes)                   \<90                                                      179 (39.6)
                                             90--179                                                   61 (13.5)
                                             180--269                                                  184 (40.7)
                                             270+                                                      28 (6.2)
  Emergency severity index triage score      2                                                         2 (0.4)
                                             3                                                         119 (26.3)
                                             4                                                         329 (72.8)
                                             5                                                         2 (0.4) 
  Chief complaint                            Influenza‐like illness                                    182 (40.3)
                                             Cough                                                     121 (26.7)
                                             Fever or chills                                           58 (12.8)
                                             COVID‐19 related                                          30 (6.6)
                                             Shortness of breath or wheezing                           26 (5.8)
                                             Sore throat                                               9 (1.9)
                                             Other upper respiratory symptoms (rhinorrhea, ear pain)   8 (1.8)
                                             Chest pain                                                8 (1.8)
                                             Other (diarrhea, body aches, malaise, headache)           10 (2.2)
  Abnormal triage vital signs                Systolic blood pressure \< 90                             0 (0)
                                             Heart rate \> 100                                         103 (22.8)
                                             Respiratory rate \> 20                                    36 (8.0)
                                             Temperature \> 100.4°F                                    19 (4.2)
                                             Oxygen saturation \< = 91% on room air                    0 (0)
  Days of symptoms prior to index ED visit   \<5                                                       238 (52.7)
                                             5 to 10                                                   143 (31.6)
                                             \>10                                                      56 (12.4)
                                             *Missing*                                                 15 (3.3)
  Testing done during index ED visit         Chest X‐ray                                               228 (50.4)
                                             EKG                                                       51 (11.3)
                                             Influenza test                                            28 (6.2)
                                             COVID‐19 test in ED                                       128 (28.3)
                                             Blood work                                                57 (12.6)
  Results                                    Infiltrate on chest X‐ray                                 32 (7.1)
                                             Influenza test positive                                   0 (0)
                                             ED COVID test positive                                    46 (10.1)
                                             Any COVID test positive during 30‐day follow‐up period    62 (13.7)
  Total duration of symptoms                 \<10 days                                                 67 (14.8)
                                             10--30 days                                               1422 (31.4)
                                             \>30 days                                                 443 (9.75)
                                             *Missing*                                                 199 (44.0)
  Outcomes                                   ED re‐visit within 30 days                                62 (13.7)
                                             Hospital admission within 30 days                         21 (4.6)
                                             ICU admission within 30 days                              3 (0.7)
                                             Median days before discharge and return for admission     5 (interquartile range 3--7)
                                             *Missing*                                                 111 (24.6)
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Thirty‐day follow up was available for 341/452 (75.4%) patients: 271/452 (60.0%) through phone follow‐up and an additional 70/452 (15.4%) through documentation in the EHR. Patient‐reported total duration of symptoms was a median of 15 days (IQR 9--17). Revisits to the ED within 30 days occurred for 62/452 (13.7%) of patients. Returns resulting in hospitalization within 30 days occurred in 21/452 (4.6%) of patients, with 3/452 (0.7%) admitted to the ICU. For patients who returned and were hospitalized within 30 days, the median number of days from the index visit to return for admission was 5 (IQR 3--7, range 1--17) and median total duration of symptoms prior to the admission was 10 (IQR 9--12, range 3--17). A majority (16/21 = 76.2%) of the patients who returned and required hospitalization were diagnosed with COVID‐19 by PCR testing within 30 days of the index ED visit. To our knowledge, the mortality rate was zero.

4. LIMITATIONS {#emp212230-sec-0190}
==============

The study is limited, first, by its retrospective nature and potential for biases introduced by incomplete clinician documentation. Second, follow‐up information (by either phone or subsequent clinical documentation) was available for only 75.4% of patients in the sample, which may have led to underestimated rates of hospitalization or mortality. Third, death certificate data were not available because of the proximity of clinical care and preparation of this manual, and mortality may have thus been underestimated. Fourth, unlike other reports focusing on patients with PCR‐proven COVID‐19, the patients in this study comprised a more heterogenous population with PCR testing performed in 45.3% with only 30.2% of those tested being positive for SARS‐CoV‐2. Fifth, members of the team reviewing ED revisits were not blinded to the study\'s intent, which may have introduced bias into assessment of those visits. Lastly, the study\'s generalizability to other settings is limited by the data coming from a single site. Because of site‐specific characteristics, it is possible that other ED sites with different availability of access to transportation and/or those who lack medical complexity may have different rates of outcomes than our own.

5. DISCUSSION {#emp212230-sec-0200}
=============

In this retrospective cohort study of 452 ambulatory patients with symptoms consistent with COVID‐19, we provide preliminary evidence that relatively young patients with reassuring pulse oximetry, respiratory rate, general appearance, and lack of significant comorbidities can self‐manage their conditions outside of the hospital. Our sample had a lower rate of ED revisits compared to the 20% rate that has been published in peer‐reviewed studies of all‐comers to the ED.[^8^](#emp212230-bib-0008){ref-type="ref"} Only a small proportion of our patients were hospitalized within 30 days (4.6%) and few required intensive care (0.7%). These outcomes provide preliminary evidence that relatively healthy patients tend to fare well after ED evaluation for COVID‐19.

The clinical progression of disease in our cohort was similar to earlier publications describing maximal symptom severity at 8--10 days after symptom onset.[^9^](#emp212230-bib-0009){ref-type="ref"} The median interval from ED discharge to ED return of 5 days is also reassuring and argues against COVID‐19 as a rapidly progressive illness or one associated with sudden onset of respiratory decompensation in younger and healthy populations. We also describe the median total duration of illness in our population to be 15 days, similar to those with "mild disease" in China.[^9^](#emp212230-bib-0009){ref-type="ref"}

Before this study, only 2 decision support tools were available to help clinicians assess the prognosis of patients with suspected viral pneumonia infection; however, neither tool is directly applicable to the US ED population during the COVID‐19 pandemic. The first is the MuLBSTA score, which requires the patient to have had chest radiography (to characterize presence or absence of infiltrate) and blood work (to determine the absolute lymphocyte count) and was developed prior to the spread of COVID‐19.[^10^](#emp212230-bib-0010){ref-type="ref"} The second is the Brescia‐COVID Respiratory Severity Scale, which requires serial chest radiography evaluation in patients with illness of at least 7 days and has not yet been validated outside of Italy.[^11^](#emp212230-bib-0011){ref-type="ref"} To our knowledge, our study is the first to evaluate outcomes among ED patients with suspected COVID‐19 infection in an environment in which physicians were given disposition guidelines. Of note, adherence to guidelines was not enforced nor audited. However, our clinical experience suggests that they have good face validity and could be a good candidate for formal testing in a future prospective trial.

In summary, low‐risk patients with suspected COVID‐19 who present to the ED can be safely discharged home. Some patients will experience progression of symptoms in the ensuing week that require hospitalization for supportive therapy, typically at 10 days of symptomatic illness. ED clinicians should explain to patients that they may experience worsening symptoms after the ED visit, such as labored breathing, which should prompt them to seek follow‐up assessment by a medical professional.
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###### 

Supplement Table A1. List of outcomes of interest at 30 days (ED revisit; inpatient hospital admission, and/or ICU admission) with accompanying descriptions of cases, including trends in oxygen saturation and patient rationale for returning to the emergency department

###### 

Click here for additional data file.
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